查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1262039

肺癌治療市場 - 全球行業規模、份額、趨勢、機會、預測，2018-2028 按癌細胞類型（非小細胞肺癌、小細胞肺癌）、治療、地區劃分

Lung Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Cancer Cell Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), By Treatment, By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺癌治療市場預計在預測期內將出現顯著增長。 推動市場增長的因素是肺癌發病率的增加和與肺癌相關的先進治療方法。

肺癌患病率增加

肺癌（包括小細胞癌和非小細胞癌）是全球第二大常見癌症。 根據美國癌症協會對 2022 年肺癌的估計，美國將有大約 236,740 名（117,910 名男性；118,830 名女性）肺癌新病例，以及大約 88,820 名女性和 60,130 名女性）死於肺癌。 此外，據估計，男性肺癌的終生患病率為 1/15，女性為 1/17。 這個數字包括吸煙者和非吸煙者。

對免疫療法的需求不斷增長

藥物、疫苗和其他刺激免疫系統自然防禦以對抗癌症的療法被稱為免疫療法。 一類稱為“抗 PD-1”的免疫治療劑已被證明可在 25% 的化療後患者中引起顯著的腫瘤消退。 三種免疫治療藥物——pembrolizumab、atezolizumab 和 nivolumab——被批准用於治療某些非小細胞肺癌。 此外，多個組織正在資助免疫療法研究，這有望促進市場擴張。 例如，2022 年，帕剋癌症免疫治療研究所與科學家和商業先驅合作，創造了一種革命性的癌症免疫治療藥物。 因此，增加對免疫療法的投資和採用正在推動全球肺癌治療市場的需求。

癌症治療的副作用

肺癌是一種慢性病，需要長期治療。 這些治療通過高劑量和長時間接觸藥物來影響人體。 與抗癌藥物相關的常見副作用包括呼吸問題、疲勞、感染、出血、貧血、胃腸道問題（噁心、嘔吐、腹瀉、便秘）、外貌變化和脫髮。 例如，化療會攻擊癌細胞，但也會影響毛囊、血液、口腔和消化系統等健康細胞。 此外，副作用因人而異，用於治療癌症的劑量也因人而異。 因此，癌症治療的副作用預計會阻礙市場增長。

近期發展

  • 2019 年 3 月，AdoRx Treatments Limited 宣布與 Johnson & Johnson Innovation LLC 和 Johnson & Johnson (LCI) Lung Cancer Initiative 結成戰略聯盟，以開發一種全新的創新型肺癌藥物。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第一章服務概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

第五章肺癌藥物全球市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按癌細胞類型
    • 通過治療

第六章北美肺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第七章：歐洲肺癌藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第八章亞太地區肺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞

第9章南美肺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章中東和非洲肺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
    • 按治療方法（化學療法、放射療法、免疫療法、靶向療法、其他治療方法）
    • 按國家
  • MEA：國家分析
    • 阿聯酋肺癌藥物
    • 沙特阿拉伯肺癌藥物
    • 南非肺癌藥物
    • Turkiye 肺癌藥物
    • 埃及肺癌藥物

第 11 章市場動態

  • 主持人
    • 肺癌患病率上升
    • 吸煙人數增加
    • 對免疫療法的需求不斷增長
  • 做
    • 昂貴的癌症治療費用
    • 關於藥物的副作用
    • 缺乏技術工人

第12章市場趨勢與發展

  • 產品發布
  • 併購
  • 技術進步

第13章臨床試驗分析

第 14 章全球肺癌藥物市場：SWOT 分析

第15章競爭格局

  • 業務概覽 提供的產品 近期發展 財務狀況（針對上市公司） 關鍵人員 SWOT 分析
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co
    • Pfizer Inc.
    • Allergan Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Abbvie, Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Novartis AG

第16章 策略建議

簡介目錄
Product Code: 14700

The global lung cancer therapeutics market is projected to witness impressive growth during the forecast period. The factors contributing to the growth of the market are the increasing incidence of lung cancer and sophisticated treatments associated with lung cancer.

Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer, which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of the high proliferation of cancer cells in the lungs.

The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines is expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.

Increasing Prevalence of Lung Cancer

Lung cancer (both small cell and non-small cell) is the second most common cancer globally. As per the American Cancer Society's estimates for lung cancer in 2022, approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) were reported in the US, and about 130,180 (68,820 men and 61,360 women) people died due to lung cancer. Further, the overall chances of lung cancer prevalence in a man for a lifetime period are 1 in 15, and for women, the risk is about 1 in 17. This number includes smokers as we non-smokers.

The rise in demand for Immunotherapy

The use of medications, vaccinations, and other therapies to stimulate the immune system's natural defenses so that it can combat cancer is known as immunotherapy. One class of immunotherapy medication known as "anti-PD-1" has been demonstrated to result in significant tumor regression in 25% of patients who get it after a round of chemotherapy. Three immunotherapy drugs-pembrolizumab, atezolizumab, and nivolumab have been approved to treat certain non-small cell lung cancers. Additionally, several organizations are funding immunotherapy research, which is anticipated to boost market expansion. For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers. Hence, rising investment and adoption of immunotherapy are fueling the demand for the global lung cancer therapeutics market.

Side Effects of cancer treatment

Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.

Market Segmentation

The global lung cancer therapeutics market is segmented based on cancer cell type, treatment, region, and company. Based on Cancer Cell Type, the market is categorized into Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC). Based on Treatment, the market is segmented into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other Treatments.

Recent Developments

  • In March 2019, AdoRx Treatments Limited announced a strategic alliance with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson (LCI) for the creation of brand-new, innovative lung cancer therapeutics.

Market Players

AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.

Report Scope

In this report, the global lung cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Lung Cancer Therapeutics Market, By Cancer Cell Type:

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

Lung Cancer Therapeutics Market, By Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Other Treatments

Lung Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lung Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
    • 5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Cancer Cell Type
    • 5.3.2. By Treatment

6. North America Lung Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lung Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Cell Type
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Lung Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Cell Type
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Cell Type
        • 6.3.3.2.2. By Treatment

7. Europe Lung Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Lung Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Cell Type
        • 7.3.1.2.2. By Treatment
    • 7.3.2. Germany Lung Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Cell Type
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Cell Type
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Lung Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Cell Type
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Lung Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Cell Type
        • 7.3.5.2.2. By Treatment

8. Asia-Pacific Lung Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Lung Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Cell Type
        • 8.3.1.2.2. By Treatment
    • 8.3.2. Japan Lung Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Cell Type
        • 8.3.2.2.2. By Treatment
    • 8.3.3. India Lung Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Cell Type
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Cell Type
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Lung Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Cell Type
        • 8.3.5.2.2. By Treatment

9. South America Lung Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Cell Type
        • 9.3.1.2.2. By Treatment
    • 9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Cell Type
        • 9.3.2.2.2. By Treatment
    • 9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Cell Type
        • 9.3.3.2.2. By Treatment

10. Middle East and Africa Lung Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Lung Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Cell Type
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Cell Type
        • 10.3.2.2.2. By Treatment
    • 10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Cell Type
        • 10.3.3.2.2. By Treatment
    • 10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Cancer Cell Type
        • 10.3.4.2.2. By Treatment
    • 10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Cancer Cell Type
        • 10.3.5.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing Prevalence of Lung Cancer.
    • 11.1.2. Rise in the number of Tobacco Smokers
    • 11.1.3. Rise in demand for Immunotherapy
  • 11.2. Challenges
    • 11.2.1. High Cost of Cancer Treatment
    • 11.2.2. Side Effects of Drugs
    • 11.2.3. Lack of skilled workforce

12. Market Trends & Developments

  • 12.1. Product Launches
  • 12.2. Mergers & Acquisitions
  • 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Lung Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (In Case of Listed Companies)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. AstraZeneca Plc
    • 15.6.2. Boehringer Ingelheim International GmbH.
    • 15.6.3. Bristol-Myers Squibb Company
    • 15.6.4. Eli Lilly and Company
    • 15.6.5. F. Hoffmann-La Roche Ltd.
    • 15.6.6. Merck & Co
    • 15.6.7. Pfizer Inc.
    • 15.6.8. Allergan Inc.
    • 15.6.9. Teva Pharmaceutical Industries Ltd.
    • 15.6.10. Abbvie, Inc.
    • 15.6.11. Johnson & Johnson
    • 15.6.12. Amgen Inc.
    • 15.6.13. Novartis AG

16. Strategic Recommendations